Efficacy outcomes for recipients of tisagenlecleucel. DOR (A), EFS (B) and OS (C) in patients with ALL, and DOR (D), PFS (E), and OS (F) in patients with NHL. CRi, CR with incomplete hematologic recovery; NE, not evaluable.